GlassScriptPhysician profile
Dustin M Pine
NPI 1619381597
$2,542.91
in general payments reported to CMS, 2019-2025
23 companies · $673 in 2025
The $673 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $322 · 2022: $373 · 2023: $430 · 2024: $744 · 2025: $673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,847.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,847.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $403.91 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $321.72 | 2021-2025 | |
| Daiichi Sankyo INC. | $223.75 | 2023-2025 | Injectafer |
| Janssen Pharmaceuticals, INC | $214.90 | 2021-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $214.30 | 2021-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.20 | 2022-2025 | Jardiance |
| Amgen INC. | $192.86 | 2021-2025 | Repatha, Repatha |
| Alnylam Pharmaceuticals INC. | $170.33 | 2023-2025 | Onpattro, Amvuttra |
| Bridgebio Pharma, INC. | $119.56 | 2025 | Attruby |
| Novo Nordisk INC | $84.95 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Impulse Dynamics (USA) INC. | $70.61 | 2022-2025 | Optimizer, Optimizer |
| Sanofi-Aventis U.S. LLC | $65.89 | 2021-2022 | |
| American Regent | $40.80 | 2024 | Injectafer |
| Lexicon Pharmaceuticals, INC. | $36.42 | 2024 | |
| Lantheus Medical Imaging, INC. | $30.52 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $28.67 | 2021-2022 | |
| Kestra Medical Technology Services, INC. | $23.79 | 2024 | Assure Wcd |
| Actelion Pharmaceuticals US, INC. | $23.79 | 2025 | Opsynvi |
| Bayer Healthcare Pharmaceuticals INC. | $18.85 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $17.96 | 2024 | Farxiga |
| Esperion Therapeutics, INC. | $15.23 | 2025 | Nexletol |
| Amarin Pharma, INC. | $15.01 | 2021 | |
| Medtronic, INC. | $14.89 | 2024 | Cg Future |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dustin Pine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.